Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
This St Nick Truly Can Advise How To Drink And Hack Your Headache - 2Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
- 3Top 20 Wellbeing and Wellness Applications for a Sound Way of life
- 4HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- 5South Korea to End Bear Bile Farming and Find New Homes for the 200 Bears Stuck in the Industry
- Kate Hudson, 46, says she doesn't need long workouts to feel good
- The Ursid meteor shower will be the last of the year, peaking just before Christmas: What to know and how to watch
- This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
- Artemis II's moonbound toilet is working again to astronauts' relief after overnight fix
- France bans Muslim gathering citing risk to participants
- How food assistance programs can feed families and nourish their dignity
- The 12 biggest space stories of 2025 — according to you
- 4 Home Rec center Hardware Decisions for Little Spaces
- An Excursion Through Renowned Western Network programs
